The drug which was synthesized in association with Control Laboratory of Food and Drug Department of Iran's Ministry of Health, Hygiene, and Medical Education can be used in MRI as the contrast agents in addition to curing cancerous tumors.
The aim of this study was to evaluate the contrast optimization of silicon-based gadolinium oxide nanoparticles with nanocomposite coating, and to compare gadolinium nanoparticle with the common contrast agent in magnetic resonance imaging (Magnevist). In this study, the new emulsion made of gadolinium oxide nanoparticle and POSS-PCU nanocomposite was investigated. In comparison with Magnevist, gadolinium oxide nanoparticles can increase the signal of MRI by reducing relaxation time or by increasing the rate of relaxation. They can also create high contrast optimization in MRI as positive contrast in comparison with iron oxide nanoparticles (negative contrast agent).
In line with targeting methods and through connecting to biocompatible materials, the new medicine has obtained other useful results in drug delivery in order to detect lymphatic glands of breast cancer and hepatic tumors.
Since the non-nanoic sample of this drug has acquired the confirmation of US Foodstuff and Medications Standard Organization, it has FDA certificate. The drug has passed the laboratorial and animal tests, and it is going to be tested on humans too.